Axsome Therapeutics (AXSM) Competitors $103.02 +1.64 (+1.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$104.02 +1.01 (+0.98%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM vs. JAZZ, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, ASND, and VRNAShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "medical" sector. Axsome Therapeutics vs. Its Competitors Jazz Pharmaceuticals Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Is AXSM or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-64.39% -272.80% -36.69% Jazz Pharmaceuticals 11.86%26.62%9.14% Does the media favor AXSM or JAZZ? In the previous week, Axsome Therapeutics had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 7 mentions for Axsome Therapeutics and 5 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.22 beat Axsome Therapeutics' score of 1.21 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, AXSM or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$385.69M13.15-$287.22M-$5.77-17.85Jazz Pharmaceuticals$4.07B1.72$560.12M$7.5015.40 Do insiders and institutionals hold more shares of AXSM or JAZZ? 81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, AXSM or JAZZ? Axsome Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Do analysts prefer AXSM or JAZZ? Axsome Therapeutics presently has a consensus target price of $172.33, suggesting a potential upside of 67.28%. Jazz Pharmaceuticals has a consensus target price of $181.64, suggesting a potential upside of 57.24%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 SummaryJazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07B$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-17.8517.6228.8523.79Price / Sales13.15309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book87.318.488.255.54Net Income-$287.22M-$55.06M$3.25B$259.88M7 Day Performance2.17%-3.99%-3.73%-4.67%1 Month Performance-0.86%9.58%4.28%4.40%1 Year Performance22.03%6.70%25.84%17.91% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.8157 of 5 stars$103.02+1.6%$172.33+67.3%+19.8%$5.07B$385.69M-17.85380Positive NewsUpcoming EarningsJAZZJazz Pharmaceuticals4.8548 of 5 stars$117.38-0.7%$181.64+54.7%+1.0%$7.10B$4.07B15.652,800Positive NewsUpcoming EarningsINSMInsmed3.7848 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.30B$363.71M-17.101,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9751 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.96B$16.62B-14.3736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6306 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$14.81B$3.12B13.122,682News CoverageUpcoming EarningsShort Interest ↑MRNAModerna4.4664 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownRDYDr. Reddy's Laboratories2.2908 of 5 stars$14.71+0.2%$16.95+15.3%-15.5%$12.28B$3.81B22.2827,811QGENQiagen3.2115 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.34B$1.98B127.875,765News CoverageUpcoming EarningsVTRSViatris2.2064 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$10.87B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0689 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.04B$368.70M-26.141,017Analyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1478 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.95B$42.28M-52.5530Positive NewsUpcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies JAZZ Alternatives INSM Alternatives TEVA Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives QGEN Alternatives VTRS Alternatives ASND Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXSM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts